Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology

J Allergy Clin Immunol. 2006 Apr;117(4 Suppl):S525-53. doi: 10.1016/j.jaci.2006.01.015.


Human immunoglobulin prepared for intravenous administration (IGIV) has a number of important uses in the treatment of disease. Some of these are in diseases for which acceptable treatment alternatives do not exist. In this review we have evaluated the evidence underlying a wide variety of IGIV uses and make specific recommendations on the basis of these data. Given the potential risks and inherent scarcity of IGIV, careful consideration of the indications for and administration of IGIV is warranted.

Publication types

  • Review

MeSH terms

  • Asthma / therapy
  • Autoimmune Diseases / therapy
  • Clinical Trials as Topic
  • Communicable Diseases / therapy
  • Cytomegalovirus Infections / etiology
  • Cytomegalovirus Infections / therapy
  • Graft Rejection / therapy
  • Humans
  • Immunization, Passive*
  • Immunoglobulins, Intravenous / administration & dosage
  • Immunoglobulins, Intravenous / adverse effects
  • Immunoglobulins, Intravenous / therapeutic use*
  • Immunologic Deficiency Syndromes / therapy
  • Kidney Transplantation / adverse effects
  • Mental Disorders / therapy
  • Nervous System Diseases / therapy
  • Respiratory Syncytial Virus Infections / etiology
  • Respiratory Syncytial Virus Infections / therapy
  • Risk
  • Skin Diseases / therapy


  • Immunoglobulins, Intravenous